A prospective, randomized, multicenter trial comparing the efficacy and safety of the concurrent use of long-acting insulin with mitiglinide or voglibose in patients with type 2 diabetes
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Son, Jang-Won | - |
dc.contributor.author | Lee, In-Kyu | - |
dc.contributor.author | Woo, Jeong-taek | - |
dc.contributor.author | Baik, Sei Hyun | - |
dc.contributor.author | Jang, Hak Chul | - |
dc.contributor.author | Lee, Kwan Woo | - |
dc.contributor.author | Cha, Bong Soo | - |
dc.contributor.author | Sung, Yeon-Ah | - |
dc.contributor.author | Park, Tae Sun | - |
dc.contributor.author | Yoo, Soon-Jib | - |
dc.contributor.author | Yoon, Kun-Ho | - |
dc.date.accessioned | 2021-09-04T09:14:26Z | - |
dc.date.available | 2021-09-04T09:14:26Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2015-12-20 | - |
dc.identifier.issn | 0918-8959 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/91554 | - |
dc.description.abstract | This trial was conducted to compare the efficacy and safety of combination therapy with basal insulin glargine plus mitiglinide to that of basal insulin glargine plus voglibosein patients with type 2 diabetes. This was a 20-week, randomized, multicenter non-inferiority trial. Patients with HbA1c levels over 7.0% were randomly assigned to receive either mitiglinide (10 mg tid) or voglibose (0.2 mg tid) concurrent with insulin glargine for 16 weeks after a 4-week of basal insulin glargine monotherapy. The intention-to-treat population included 156 patients; 79 were placed in the mitiglinide group, and 77 were placed in the voglibose group. At 20 weeks, there was no significant difference between the mitiglinide group and the voglibose group in terms of the mean HbA1c level or the mean decrease of the HbA1c level from baseline (-0.9% [-7.5 mmol/mol] and 0.7%, [-5.3 mmol/mol] respectively). The mean fasting plasma glucose level and data of self-monitoring blood glucosewere significantly decreased from baseline to week 20 in both groups, but there was no significant difference between the two groups. The changes in the basal insulin requirements of each group were not significant. The prevalence of adverse events and the risk of hypoglycemia were similar for both groups. Combination therapy with mitiglinide plus basal insulin glargine was non-inferior to voglibose plus basal insulin glargine in terms of the effect on overall glycemic control. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | JAPAN ENDOCRINE SOC | - |
dc.subject | GLYCEMIC CONTROL | - |
dc.subject | GLUCOSE CONTROL | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | SHORT-TERM | - |
dc.subject | NATEGLINIDE | - |
dc.subject | GLARGINE | - |
dc.subject | MELLITUS | - |
dc.subject | THERAPY | - |
dc.subject | COMBINATION | - |
dc.subject | ACARBOSE | - |
dc.title | A prospective, randomized, multicenter trial comparing the efficacy and safety of the concurrent use of long-acting insulin with mitiglinide or voglibose in patients with type 2 diabetes | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Baik, Sei Hyun | - |
dc.identifier.doi | 10.1507/endocrj.EJ15-0325 | - |
dc.identifier.scopusid | 2-s2.0-84952048636 | - |
dc.identifier.wosid | 000368316500002 | - |
dc.identifier.bibliographicCitation | ENDOCRINE JOURNAL, v.62, no.12, pp.1049 - 1057 | - |
dc.relation.isPartOf | ENDOCRINE JOURNAL | - |
dc.citation.title | ENDOCRINE JOURNAL | - |
dc.citation.volume | 62 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 1049 | - |
dc.citation.endPage | 1057 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Endocrinology & Metabolism | - |
dc.relation.journalWebOfScienceCategory | Endocrinology & Metabolism | - |
dc.subject.keywordPlus | GLYCEMIC CONTROL | - |
dc.subject.keywordPlus | GLUCOSE CONTROL | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | SHORT-TERM | - |
dc.subject.keywordPlus | NATEGLINIDE | - |
dc.subject.keywordPlus | GLARGINE | - |
dc.subject.keywordPlus | MELLITUS | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | ACARBOSE | - |
dc.subject.keywordAuthor | Diabetes mellitus | - |
dc.subject.keywordAuthor | Type 2 | - |
dc.subject.keywordAuthor | Mitiglinide | - |
dc.subject.keywordAuthor | Voglibose | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.